Merck KGaA has agreed to acquire US-based Bio-Techne for $11.3 billion, marking a significant expansion of the German company’s presence in the life-sciences research market.
The deal, reported by Hindu Businessline, underscores Merck’s strategy to strengthen its capabilities in biological research tools and reagents through strategic M&A activity.
The acquisition targets Bio-Techne, a provider of research tools and services for the life-sciences community.
By integrating Bio-Techne’s portfolio, Merck aims to enhance its offering in high-growth areas such as cell culture, proteomics, and genomics.
This move aligns with broader industry trends where large-cap chemical and pharmaceutical companies are acquiring specialized biotech firms to diversify revenue streams and capture growth in the research sector.
Merck KGaA, distinct from its US pharmaceutical namesake Merck & Co., has been actively reshaping its business mix.